Design Therapeutics, Inc. DSGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $58.13M-1.7% | $59.13M+2.2% | $57.86M+4.9% | $55.15M+10.5% | $49.93M+12.6% | ||
| $20.62M+1.4% | $20.34M+1.0% | $20.13M+1.8% | $19.78M+7.1% | $18.48M+2.5% | ||
| $78.76M-0.9% | $79.47M+1.9% | $77.99M+4.1% | $74.93M+9.5% | $68.4M+9.6% | ||
| -$78.76M+0.9% | -$79.47M-1.9% | -$77.99M-4.1% | -$74.93M-9.5% | -$68.4M-9.6% | ||
| —— | —— | —— | —— | —— | ||
| -$69.71M+0.1% | -$69.79M-3.5% | -$67.45M-6.2% | -$63.49M-13.0% | -$56.2M-13.3% | ||
| -$1.20+1.6% | -$1.22-2.5% | -$1.19-6.3% | -$1.12-13.1% | -$0.99-12.5% | ||
| -$78.14M+0.9% | -$78.85M-1.9% | -$77.38M-4.1% | -$74.31M-9.6% | -$67.79M-9.7% | ||
| -$78.76M+0.9% | -$79.47M-1.9% | -$77.99M-4.1% | -$74.93M-9.5% | -$68.4M-9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Design Therapeutics, Inc. profitable?
- Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
- What is Design Therapeutics, Inc.'s earnings per share?
- Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
- Where does Design Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.